Citizens Maintains Market Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $95

Benzinga Newsdesk www.benzinga.com Negative 95.2%

Neg 95.2% Neu 0% Pos 0%

Citizens analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and lowers the price target from $97 to $95.